{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:26:14Z","timestamp":1793989574499,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["BHF 1005759"],"award-info":[{"award-number":["BHF 1005759"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiovascular Magnetic Resonance"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.jocmr.2025.101846","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T12:29:29Z","timestamp":1737894569000},"page":"101846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inequity of access to contrast-enhanced cardiovascular magnetic resonance in patients with chronic kidney disease: A survey from the British Society of Cardiovascular Magnetic Resonance"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-618X","authenticated-orcid":false,"given":"William E.","family":"Moody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayisha Mehtab","family":"Khan-Kheil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Naneishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy E.","family":"Hudsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Captur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Treibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry P.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul G.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall G.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jocmr.2025.101846_bib1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jaad.2010.08.041","article-title":"Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations","volume":"65","author":"Girardi","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jocmr.2025.101846_bib2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.jocmr.2025.101846_bib3","unstructured":"FDA Drug Safety Communication. New warnings for using gadolinium based contrast agents in patients with kidney dysfunction. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney (accessed May 31, 2024)."},{"key":"10.1016\/j.jocmr.2025.101846_bib4","unstructured":"ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, version 10.3. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/Clinical-Resources\/Contrast_Media.pdf (accessed May 31, 2024)."},{"issue":"2","key":"10.1016\/j.jocmr.2025.101846_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocmr.2025.101846_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1532-429X-13-57","article-title":"Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance","volume":"13","author":"Antony","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2025.101846_bib7","first-page":"A14.3","article-title":"Cardiovascular magnetic resonance activity in the United Kingdom: results of the 2014 BSCMR survey","volume":"101","author":"Ripley","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.jocmr.2025.101846_bib8","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1136\/heartjnl-2020-318667","article-title":"Regional variation in cardiovascular magnetic resonance service delivery across the UK","volume":"107","author":"Keenan","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.jocmr.2025.101846_bib9","unstructured":"RCR Publications guidance on gadolinium based contrast agent administration to adult patients; April 2019. https:\/\/www.rcr.ac.uk\/our-services\/all-our-publications\/clinical-radiology-publications\/guidance-on-gadolinium-based-contrast-agent-administration-to-adult-patients\/ (accessed May 31, 2024)."},{"key":"10.1016\/j.jocmr.2025.101846_bib10","unstructured":"American College of Radiology. Manual on contrast media. Version 10.3. Reston, VA: American College of Radiology; 2018. https:\/\/www.acr.org\/Clinical-Resources\/Contrast-Manual (accessed May 31, 2019)."},{"issue":"2","key":"10.1016\/j.jocmr.2025.101846_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.jocmr.2025.101846_bib12","first-page":"285","article-title":"Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol","volume":"3","author":"Elmholdt","year":"2010","journal-title":"NDT"},{"issue":"12","key":"10.1016\/j.jocmr.2025.101846_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082037","article-title":"Nephrogenic systemic fibrosis in Denmark--a nationwide investigation","volume":"8","author":"Elmholdt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jocmr.2025.101846_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2020202903","article-title":"Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"298","author":"Jeffrey","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.jocmr.2025.101846_bib15","unstructured":"ESUR guidelines on contrast agents. Version 10.0. Chapter A.3.2. Published March 2018. http:\/\/www.esur.org\/fileadmin\/content\/2019\/ESUR_Guidelines_10.0_Final_Version.pdf (accessed December 18, 2024)."},{"issue":"3","key":"10.1016\/j.jocmr.2025.101846_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.carj.2019.04.001","article-title":"Updated clinical practice guideline on use of gadolinium-based contrast agents in kidney disease issued by the Canadian Association of Radiologists","volume":"70","author":"Schieda","year":"2019","journal-title":"Can Assoc Radiol J"}],"container-title":["Journal of Cardiovascular Magnetic Resonance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1097664725000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1097664725000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:52:13Z","timestamp":1793987533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1097664725000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["S1097664725000080"],"URL":"https:\/\/doi.org\/10.1016\/j.jocmr.2025.101846","relation":{},"ISSN":["1097-6647"],"issn-type":[{"value":"1097-6647","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inequity of access to contrast-enhanced cardiovascular magnetic resonance in patients with chronic kidney disease: A survey from the British Society of Cardiovascular Magnetic Resonance","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiovascular Magnetic Resonance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocmr.2025.101846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Society for Cardiovascular Magnetic Resonance.","name":"copyright","label":"Copyright"}],"article-number":"101846"}}